Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.
– Consistent safety and efficacy profiles across adult and pediatric populations –
TARRYTOWN, N.Y., April 07, 2024 -- Regeneron Pharmaceuticals, Inc. today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of...
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 -- Regeneron...
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...